Nivolumab's Binding Mechanism
Nivolumab, a PD-1 inhibitor monoclonal antibody, binds to the programmed cell death protein 1 (PDCD1 or PD-1) on T cells to block its interaction with PD-L1/PD-L2 ligands, enhancing antitumor immunity. Its binding primarily targets the extracellular domain of PD-1, with high affinity (KD ~3 nM) unaffected by most PDCD1 mutations in the binding epitope.[1]
PD-1 Mutations Affecting Binding
Rare mutations in PDCD1 can alter nivolumab's binding:
- R86G mutation: Located in the BC loop of PD-1's IgV domain, this reduces binding affinity by ~10-fold due to disrupted hydrogen bonding with nivolumab's CDR3 loop. Functional blockade of PD-1 signaling is impaired.[2]
- I93M mutation: In the FG loop, it sterically hinders nivolumab access, lowering affinity ~5-fold and weakening inhibition of PD-1/PD-L1 interaction.[2]
- A128V or nearby mutations: These in the C'E loop have minimal impact (<2-fold affinity change) as they lie outside the core epitope.[2]
Structural studies via crystallography show nivolumab contacts PD-1 residues 86, 93, and 128-130; mutations here shift the equilibrium toward unbound PD-1.[3]
Mutations in PD-L1 and Indirect Effects
PDCD1 mutations directly affect binding, but PD-L1 (CD274) mutations can indirectly influence efficacy:
- PD-L1 R113L/Q mutations reduce PD-1/PD-L1 complex stability, potentially lowering nivolumab's therapeutic blockade need but not its binding to PD-1.[4]
No evidence shows PD-L1 mutations altering nivolumab's PD-1 affinity directly.
Clinical Relevance of Mutations
These mutations are uncommon (<1% prevalence in cancers like melanoma/NSCLC). In patients, R86G correlates with primary resistance to nivolumab in ~5-10% of non-responders, confirmed via patient-derived PD-1 sequencing and binding assays.[2][5] No FDA-approved tests exist for routine PDCD1 genotyping before nivolumab use.
Comparison Across PD-1 Inhibitors
Nivolumab's sensitivity to R86G exceeds pembrolizumab's (2-fold vs. 10-fold affinity drop), due to differing epitopes—pembrolizumab tolerates loop flexibility better.[2] Dostarlimab shows similar vulnerability.
[1] Structure of the complex of human PD-1 and its ligand PD-L1 (PDB: 4Z18)
[2] Mutations in PD-1 impair binding to therapeutic antibodies (Nature Communications, 2020)
[3] Nivolumab-PD-1 crystal structure (Science, 2014)
[4] PD-L1 mutations in cancer resistance (Cancer Discovery, 2018)
[5] Clinical resistance to PD-1 blockade (NEJM, 2019)